相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation- positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2023)
DHX38 restricts chemoresistance by regulating the alternative pre-mRNA splicing of RELL2 in pancreatic ductal adenocarcinoma
Zeru Li et al.
PLOS GENETICS (2023)
The splicing factor DHX38/PRP16 is required for ovarian clear cell carcinoma tumorigenesis, as revealed by a CRISPR-Cas9 screen
Brandon Cona et al.
FEBS OPEN BIO (2022)
RAF-MEK-ERK pathway in cancer evolution and treatment
Rahim Ullah et al.
SEMINARS IN CANCER BIOLOGY (2022)
Retinitis pigmentosa-linked mutation in DHX38 modulates its splicing activity
Mina Obuca et al.
PLOS ONE (2022)
EGFR Signaling in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Therapeutic Opportunities
Silvia La Monica
CELLS (2022)
Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL) : a multicentre, open-label, single-arm, phase 2 study
Reinhard Dummer et al.
LANCET ONCOLOGY (2022)
FOXD1-dependent RalA-ANXA2-Src complex promotes CTC formation in breast cancer
Yufei Long et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)
A renewed concept on the MAPK signaling pathway in cancers: Polyphenols as a choice of therapeutics
Juhaer Anjum et al.
PHARMACOLOGICAL RESEARCH (2022)
Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives
Evgeny N. Imyanitov et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)
Anticancer drug resistance: An update and perspective
Ruth Nussinov et al.
DRUG RESISTANCE UPDATES (2021)
MEK inhibitors for the treatment of non-small cell lung cancer
Jing Han et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
HIF-1α switches the functionality of TGF-β signaling via changing the partners of smads to drive glucose metabolic reprogramming in non-small cell lung cancer
Yiwei Huang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
STOML2 interacts with PHB through activating MAPK signaling pathway to promote colorectal Cancer proliferation
Wenhui Ma et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
G3BP1 inhibits Cul3SPOP to amplify AR signaling and promote prostate cancer
Chandrani Mukhopadhyay et al.
NATURE COMMUNICATIONS (2021)
Mex3a promotes oncogenesis through the RAP1/MAPK signaling pathway in colorectal cancer and is inhibited by hsa-miR-6887-3p
Haixia Li et al.
CANCER COMMUNICATIONS (2021)
Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy
J. Remon et al.
ANNALS OF ONCOLOGY (2021)
Interplay between MAPK/ERK signaling pathway and MicroRNAs: A crucial mechanism regulating cancer cell metabolism and tumor progression
Elmira Roshani Asl et al.
LIFE SCIENCES (2021)
Research Progress on the Structure and Function of G3BP
Weifang Kang et al.
FRONTIERS IN IMMUNOLOGY (2021)
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
J. Mazieres et al.
ANNALS OF ONCOLOGY (2020)
Telmisartan inhibits oxalate and calcium oxalate crystal-induced epithelial-mesenchymal transformation via PPAR-γ-AKT/STAT3/p38 MAPK-Snail pathway
Yadong Liu et al.
LIFE SCIENCES (2020)
Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
Ufuk Degirmenci et al.
CELLS (2020)
G3BP1 Is a Tunable Switch that Triggers Phase Separation to Assemble Stress Granules
Peiguo Yang et al.
CELL (2020)
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Ralf Gutzmer et al.
LANCET (2020)
The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy
Jimin Yuan et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Reinhard Dummer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Targeting EMT in Cancer with Repurposed Metabolic Inhibitors
Vignesh Ramesh et al.
TRENDS IN CANCER (2020)
Update 2020: Management of Non-Small Cell Lung Cancer
Mariam Alexander et al.
LUNG (2020)
The roles and mechanisms of G3BP1 in tumour promotion
Cong-Hui Zhang et al.
JOURNAL OF DRUG TARGETING (2019)
Targeting the ERK Signaling Pathway in Melanoma
Paola Savoia et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Kirsten L. Bryant et al.
NATURE MEDICINE (2019)
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition
Helen Adderley et al.
EBIOMEDICINE (2019)
Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance
Micol Eleonora Fiori et al.
MOLECULAR CANCER (2019)
Targeting ERK1/2 protein-serine/threonine kinases in human cancers
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2019)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Cathy Eng et al.
LANCET ONCOLOGY (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer A Review
Kathryn C. Arbour et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Narjust Duma et al.
MAYO CLINIC PROCEEDINGS (2019)
G3BP1 promotes DNA binding and activation of cGAS
Zhao-Shan Liu et al.
NATURE IMMUNOLOGY (2019)
EMT Transition States during Tumor Progression and Metastasis
Ievgenia Pastushenko et al.
TRENDS IN CELL BIOLOGY (2019)
A G3BP1-Interacting lncRNA Promotes Ferroptosis and Apoptosis in Cancer via Nuclear Sequestration of p53
Chao Mao et al.
CANCER RESEARCH (2018)
HCC-derived exosomes elicit HCC progression and recurrence by epithelialmesenchymal transition through MAPK/ ERK signalling pathway
Lu Chen et al.
CELL DEATH & DISEASE (2018)
Confirmation of the Role of DHX38 in the Etiology of Early-Onset Retinitis Pigmentosa
Zahid Latif et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)